In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cell Genesys Inc.

Division of ANI Pharmaceuticals Inc.
www.cellgenesys.com

Latest From Cell Genesys Inc.

Argos Aims To Automate Cell-Based Cancer Therapy

Eventually, someone is going to have clinical and commercial success with a personalized cancer therapy. Learning from the mistakes of Dendreon and others, Argos Therapeutics expects to be first, and automation is its key.

BioPharmaceutical

BioNotebook: Two new VC funds and a financing: Venrock, Accelerator, Cold Genesys

Venrock has completed fundraising for a new $450m pool of money that will be invested in high-tech and health care companies on the heels of Sofinnova's new $500m venture capital fund for biotech investments (scripintelligence.com, 26 July 2014).

Metabolic Disorders Cancer

Anthera acquires troubled Sollpura from Lilly

Anthera Pharmaceuticals acquired Sollpura (liprotamase), a non-porcine pancreatic enzyme replacement therapy (PERT) with a long and troubled history in exocrine pancreatic insufficiency (EPI), from Eli Lilly for an undisclosed price.

Gastrointestinal Dermatology

Janssen gains immunotherapies, boosts prostate portfolio with Aduro deal

Johnson & Johnson's Janssen Biotech will pay up to $359m in upfront and milestone fees plus royalties to expand the companies' Zytiga-led prostate cancer portfolio with programs based on Aduro BioTech's immunotherapy technology.

Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ANI Pharmaceuticals Inc.
  • Senior Management
  • Stephen A Sherwin, MD, Chmn. & CEO
    Peter K Working, PhD, SVP, R&D
  • Contact Info
  • Cell Genesys Inc.
    Phone: (650) 266-3000
    400 Oyster Point Blvd.
    Ste. 525
    S. San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register